Lao Saal, a cancer researcher at Lund University who survived leukaemia as a teenager and went on to develop a blood test – Pathlight – that can detect signs of breast cancer relapse a median of 13.7 months earlier than conventional methods, and in some cases up to three to four years earlier. The test works by identifying unique chromosomal rearrangements in tumour DNA circulating in the bloodstream (liquid biopsy). It launched in the US for breast and colon cancer, received Medicaid coverage in May 2025, and is already being used clinically. In 2016, Saal co-founded SAGA Diagnostics with PhD student Anthony George and LU Ventures, growing the company out of Lund Innovation District. The early years were lean, and a commercial path was far from guaranteed – an innovation scout from Lund University's office was the one who first pushed Saal to explore patenting and company formation. In spring 2026, Foundation Medicine (Roche) announced the acquisition of SAGA Diagnostics in a deal valued at up to USD 595 million. For Saal, the significance lies less in the sum than in what it enables: getting the technology to as many patients as possible.

Since the introduction of the Da Vinci® robotic system, robot-assisted colon resection has gained popularity because of its the potential technical advantages. 

A research team led by Dr. Hyun-Soo Cho at the Stem Cell Convergence Research Center of the Korea Research Institute of Bioscience and Biotechnology (KRIBB), in collaboration with Professor Geun Heo of Kyungpook National University, has identified a key mechanism underlying 5-FU resistance in colorectal cancer and proposed a new therapeutic strategy to restore tumor sensitivity to treatment.

A new study in Science Bulletin presents DVSTP, a deep learning system that integrates pathology images with spatial transcriptomics and proteomics to map intra-tumor heterogeneity. DVSTP predicts molecular profiles from routine pathology slides, making spatial multi-omics more accessible. Whole–tumor 3D reconstruction reveals that SRSF6 drives immune exclusion and is associated with poor clinical outcomes.